Obesity BMI Liraglutide

In obese adolescents, the use of liraglutide combined with lifestyle intervention can significantly reduce BMI

At present, the treatment of obesity in children is very limited. Recently, researchers investigated the therapeutic effect of Liraglutide on obese adolescents.

Obese adolescents aged 12-18 years old who had no significant effect on lifestyle change participated in the study. On the basis of lifestyle intervention, they were randomly given Liraglutide (3.0 mg) or placebo once a day by subcutaneous injection. The primary end point of the study was the change in the standard deviation score of body mass index (BMI) and baseline at week 56.

125 participants received Liraglutide and 126 received placebo. At week 56, the standard deviation score of BMI in the Liraglutide group was better than that in the placebo group (estimated difference: - 0.22). The BMI of 51 of 113 subjects in theLiraglutide group and 20 of 105 subjects in the placebo group decreased by at least 5% (43.3% vs 18.7%) and 33 and 9 participants respectively by at least 10% (26.1% vs 8.1%). Compared with placebo, the reduction of BMI (estimated difference of - 4.64%) and body weight (absolute change of - 4.50kg, relative change of - 5.01%) was more significant. There were more gastrointestinal adverse events (64.8% vs 36.5%) and more adverse events (10.4% vs 0) leading to the termination of the trial in the lilalutide group, but the rate of serious adverse events among the groups was lower.

In obese adolescents, the use of liraglutide combined with lifestyle intervention can significantly reduce BMI.

Original source:

Aaron S. Kelly et al. A Randomized, Controlled Trial of Liraglutide for Adolescents with Obesity. N Engl J Med, May 28, 2020.